Rosenthal E., Fougerou-Leurent C, Renault A., Carrieri Mp., Marcellin F., Garraffo R, Teicher E., Aumaitre H, Lacombe K., Bailly F., Billaud E., Chevaliez S., Dominguez S, Valantin Ma., Reynes Jacques, Naqvi A., Cotte L, Metivier S, Leroy V., Dupon M., Allegre T., de Truchis P., Jeantils V., Chas J, Salmon-Ceron D, Morlat P, Neau D, Perré P, Piroth L, Pol S., Bourlière M., Pageaux Georges Philippe, Alric Laurent, Zucman D., Girard Pm., Poizot-Martin I, Yazdanpanah Y, Raffi F., Pabic E, Tual C., Pailhé A, Amri I, Bellissant E., Molina J. M.. Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study). HIV Medicine. 2018;19(3):227-237.